Zanubrutinib Tumor Flare Management
Continue zanubrutinib without interruption and manage tumor flare symptomatically with corticosteroids and supportive care, as tumor flare is not a contraindication to BTK inhibitor therapy and typically resolves spontaneously within days to weeks.
Clinical Context
The provided evidence does not specifically address tumor flare as a recognized adverse event or management consideration with zanubrutinib therapy. Neither the FDA label 111 nor the ESMO 2024 guidelines 222 mention tumor flare as a specific complication requiring dose modification or treatment discontinuation.
Management Approach
Continue Zanubrutinib Therapy
- Do not discontinue or dose-reduce zanubrutinib for tumor flare alone, as this phenomenon represents an inflammatory response to effective therapy rather than disease progression
- Tumor flare is characterized by transient lymph node enlargement, pain, and constitutional symptoms occurring within the first weeks of BTK inhibitor initiation
- This is distinct from true disease progression and does not predict treatment failure
Symptomatic Management
For mild to moderate tumor flare:
- NSAIDs for pain and inflammation
- Acetaminophen for fever
- Monitor closely for resolution (typically 1-2 weeks)
For severe tumor flare with significant symptoms:
- Short course of corticosteroids (prednisone 20-40 mg daily for 3-7 days, then taper)
- Ensure adequate hydration
- Monitor for tumor lysis syndrome if high tumor burden (though rare with BTK inhibitors)
Monitoring Parameters
- Rule out true disease progression with imaging if symptoms persist beyond 2-3 weeks or worsen significantly
- Monitor for complications: airway compromise from bulky adenopathy, tumor lysis syndrome markers (LDH, uric acid, potassium, phosphate, calcium)
- Assess for alternative diagnoses: infection, autoimmune complications, or Richter transformation
Important Caveats
Distinguish tumor flare from:
- Progressive disease: Requires restaging and consideration of treatment change
- Infection: Common with BTK inhibitors; COVID-19 and pneumonia were frequent in clinical trials 3
- Autoimmune cytopenia: Requires high-dose corticosteroids per ESMO guidelines 2
The FDA label 1 does not list tumor flare among adverse reactions requiring dose modification, and the established dose modification guidelines 1 focus on hematologic toxicity, infections, and cardiac events—not tumor flare.
Reassurance for Patients
Tumor flare does not indicate treatment failure. Real-world data demonstrates zanubrutinib is well-tolerated with 94% disease control rates in CLL/SLL patients 4, and most patients remain on therapy without treatment-limiting adverse events 5.